Yinghong Shi

20PUBLICATIONS
34CO-AUTHORS
Molecular targetsHaematological tumoursGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jun 02, 2026
Combined MEK1/2 and Autophagy Inhibition Suppresses Tumor Growth via STING-Mediated Type I Interferon Response in iCCA.

|Dec 19, 2025
DNMT2-m5C-ACLY Axis Promotes Lenvatinib Resistance in Hepatocellular Carcinoma Through Histone Acetylation-Mediated Notch Pathway.

Shiguang Yang, Jie Li, Shengwei Mao

|Nov 24, 2025
Targeting CREB3L2-mediated lipid metabolism overcomes lenvatinib resistance and attenuates the progression of hepatocellular carcinoma.

Shiguang Yang, Shaoqing Liu, Jie Li

|Jul 22, 2025
Metabolism archetype cancer cells induce protumor TREM2<sup>+</sup> macrophages via oxLDL-mediated metabolic interplay in hepatocellular carcinoma.

Tianhao Chu, Guiqi Zhu, Zheng Tang

|May 02, 2025
Targeting HMGB2 acts as dual immunomodulator by bolstering CD8<sup>+</sup> T cell function and inhibiting tumor growth in hepatocellular carcinoma.

Wei-Feng Qu, Gui-Qi Zhu, Rui Yang

|Mar 06, 2025
Sintilimab plus bevacizumab followed by resection in intermediate-stage hepatocellular carcinoma: a phase Ib clinical trial with biomarker analysis.

Hui-Chuan Sun, Xiao-Dong Zhu, Zi-Yi Wang

Pageof 4

Frequent Collaborators

6 joint publications

Jian Zhou

4 joint publications

Guiqi Zhu

4 joint publications

Jia Fan

3 joint publications

Weiren Liu